Dr. Arpit Jayswal, Founder and CEO of PhleboIndia
New Delhi (India), January 31: PhleboIndia is a cloud-based aggregator platform in Gurugram that serves as a comprehensive solution for laboratory test home sample collection. The platform manages the entire supply chain, including the training and logistics of phlebotomists, and facilitates the collection and dispatch of samples from any location at the patient’s convenience. Toward this goal, PhleboIndia seeks to ease the process of getting tests done. With more than 1000 partner labs across India, their phlebotomist reaches the patient within 60 minutes for a free home sample collection, saving time and effort as well as travel costs for the patient.
The majority of patients nowadays, particularly in India, who belong to the middle and lower classes, are required to pay for all diagnostic tests out of their own pockets, which places a considerable financial strain on their limited budgets. By offering a no-cost EMI option on lab test bookings through PhleboIndia, Dr. Arpit hopes to lessen this burden for such patients.
Dr. Arpit Jayswal is the founder and chief executive officer (CEO) of PhleboIndia. He is both a laparoscopic and a general surgeon. Having done his M.B.B.S. from Bangalore and post-graduation in Master of Surgery from Baroda, Dr. Arpit has earned multiple fellowships in minimally invasive surgery and laser proctology and also has experience running a chain of hospitals for the past three years in Vadodara and Anand districts.
During the COVID-19 pandemic, when proper diagnosis became crucial for everyone worldwide, Dr. Arpit, who has more than 10 years of experience in the healthcare field, worked with a large number of patients. “This is a fresh idea for the diagnostics sector,” he says, “where we can use technology to deliver time-bound and standardized doorstep services for blood sample collection with the goal of making it comfortable for patients and the affiliated labs.”
“We have all experienced COVID scenarios, but comorbidity appears to be more prevalent in patients with obesity, heart disease, kidney problems, diabetes, and hypertension, according to our examination of the data,” says Dr. Arpit Jayswal. India has more heart-related ailments than other nations due to its way of life and diet. He contends that maintaining a regular blood test schedule, as well as a healthy diet and lifestyle habits, will naturally lengthen one’s life expectancy. Stating Dr. Arpit Jayswal’s unique perspective on this, he said, “We’re only an online aggregator platform, not a lab, where we give patients the choice of their preferred lab.”
He claims that for a variety of reasons, including the doctor’s confidence, the majority of patients have relied on the services of the affiliated labs to perform the tests for many years. He did not want to alter the laboratories because the patients have been using them for years. This prompted us to come up with the slogan “Your Lab at Your Place,” which promises that labs will be comfortable wherever clients choose to go.
Dr. Arpit has also received numerous honors from Icons of Asia, including “Most Dynamic Entrepreneur of the Year, 2022.” At the Iconic Business Summit, PhleboIndia was also recognized as the “Health Tech Startup of the Year.”
Recently, PhleboIndia raised Rs 5 crore in a funding round in less than four months of operation due to its patient-centric business model. In their pre-seed round of funding, the unique health-tech start-up, founded in May 2022, was valued at Rs 71.45 crore. Over the last four months, PhleboIndia has touched the lives of over 25,000 patients through its user-friendly website and mobile application.
About the milestone achieved by PhleboIndia, on an enthusiastic note, Dr. Arpit Jayswal said, “On our unique concept for the diagnostics industry, it is great to have investors show trust in our potential to scale up and take this unique concept to new heights.” Moreover, the new valuation we stand at will take us a step closer to having a pan-India operation. Outlining the idea behind his initiative, the founder continued, “As a doctor, I strongly believe that it’s my moral duty to provide an accurate diagnosis to the patient, with an aim to reach all corners of the country and make sure patients do not face any trouble due to a delay in their diagnostic tests in case of emergencies.”
As part of its long-term expansion plan, capitalizing on its current growth rate, PhleboIndia has envisioned its presence in over 200 cities across India by 2025, including tier 1, 2, 3, and 4 cities. The initiative has the goal of serving over 10,000 patients per day in the next three years. Consequently, to realize this large-scale operation, the company is on its way to employing more than 2,000 phlebotomists in the next three years.
For more information:
Website link: https://www.phleboindia.com/
Mobile Application Links:
https://play.google.com/store/apps/details?id=com.phleboindia
https://apps.apple.com/us/app/phleboindia/id1639093821
If you have any objection to this press release content, kindly contact pr.error.rectification[at]gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.
